Published Paper Details:

Patients diagnosed with type 2 diabetes (T2DM) face a significant risk of developing cardiovascular disease due to the profound impact of hyperglycemia and associated metabolic changes on vascular health. This underscores the urgent need for therapeutic advancements targeting not only glycemic control but also other metabolic risk factors to mitigate cardiovascular complications such as cardiovascular death, myocardial infarction, stroke, unstable angina, and heart failure (collectively termed major adverse cardiovascular events). In recent years, the introduction of glucagon-like peptide-1 receptor agonists (GLP-1RAs) has revolutionized T2DM treatment. GLP-1RAs exert their beneficial effects through various mechanisms, including appetite regulation, glucose-dependent insulin secretion, and inhibition of glucagon release. Importantly, these drugs have shown additional benefits extending to cardiovascular outcomes. Large-scale clinical trials have confirmed the cardiovascular efficacy of GLP-1RAs in patients with T2DM at high risk of cardiovascular disease, demonstrating promising results. However, while these findings are promising, several crucial aspects remain to be fully understood, such as the specific mechanisms underlying the cardioprotective effects of GLP-1RAs. Interpretation of trial data requires careful consideration due to variability across studies in terms of how cardiovascular risk or disease is defined, patient characteristics, standard care protocols, and event rates. This review aims to comprehensively outline the clinical profiles of GLP-1RAs, drawing on evidence from both mechanistic studies and randomized controlled trials. It also seeks to explore potential reasons behind the observed improvements in cardiovascular outcomes in these trials. By synthesizing this information, clinicians can make informed decisions regarding the most appropriate treatment strategies for reducing cardiovascular risk in patients with T2DM.